Short bowel syndrome

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with teduglutide under the National Health Act 1953, section 100 for patients with type III short bowel syndrome with intestinal failure.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing teduglutide.

Section 100 arrangements

Teduglutide

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

an approved private hospital
a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Treatment specifics

To be eligible for PBS-subsidised treatment with teduglutide, patients must be treated by a gastroenterologist or by a specialist within a multidisciplinary intestinal rehabilitation unit.

Authority applications

Applying for initial treatment

Please note: You don’t need to complete this application in writing when you request PBS authority online.

Applications for initial authority approval to prescribe PBS-subsidised teduglutide to treat short bowel syndrome can be made either:

using the Online PBS Authorities system
in writing and use HPOS Form upload
in writing and mail to PBS Complex Drugs Programs.

All written applications must include:

details of the proposed prescription or prescriptions
the completed short bowel syndrome with intestinal failure - teduglutide - initial authority application form
relevant attachments.

Applying for continuing treatment

Please note: You don’t need to complete this application in writing when you request PBS authority online.

Applications for continuing authority approval to prescribe PBS-subsidised teduglutide to treat short bowel syndrome can be made either:

using the Online PBS Authorities system
in writing and use HPOS Form upload
in writing and mail to PBS Complex Drugs Programs.